Showing 1421-1430 of 10594 results for "".
Targeting B7-H3 in ES-SCLC: Advancing Targeted Therapy Through Evidence-Based Innovation and Multidisciplinary Care
https://reachmd.com/programs/cme/targeting-b7-h3-in-es-sclc-advancing-targeted-therapy-through-evidence-based-innovation-and-multidisciplinary-care/36232/Explore the rationale and emerging efficacy and safety data for B7-H3–targeted ADCs in ES-SCLC to support patient selection and multidisciplinary care.Retina Rumble: Debating Modern Treatment Options
https://reachmd.com/programs/cme/retina-rumble-debating-modern-treatment-options/54609/Join this lively case-based debate moderated by Dr. Goldberg on selecting second-generation therapies for retinal diseases with Drs. Modi and Weng.Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
https://reachmd.com/programs/cme/data-driving-recent-guideline-updates-in-neoadjuvant-therapy-for-resectable-melanoma/36322/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
https://reachmd.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-braf-mutant-stage-iv-melanoma/36328/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
https://reachmd.com/programs/cme/emerging-and-practice-changing-data-in-immunotherapy-strategies-for-melanoma/36330/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
https://reachmd.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iibiic-melanoma/36324/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
https://reachmd.com/programs/cme/clinical-data-prompting-guideline-updates-for-subcutaneous-icis-in-melanoma/36329/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
https://reachmd.com/programs/cme/clinical-implications-of-neoadjuvant-therapy-guideline-updates-in-resectable-melanoma/36323/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Advancing Care in Locally Advanced HNSCC: Integrating Perioperative Immunotherapy and Multimodal Strategies
https://reachmd.com/programs/cme/advancing-care-in-locally-advanced-hnscc-integrating-perioperative-immunotherapy-and-multimodal-strategies/35704/Explore perioperative immunotherapy and multimodal strategies to optimize patient outcomes in resectable locally advanced head and neck squamous cell carcinoma.Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
https://reachmd.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iiiiv-melanoma/36325/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.